A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer ; volume:202 ; number:3 ; day:7 ; month:9 ; year:2023 ; pages:485-496 ; date:12.2023
Breast cancer research and treatment ; 202, Heft 3 (7.9.2023), 485-496, 12.2023
- Creator
-
Takada, Masahiro
Imoto, Shigeru
Ishida, Takanori
Ito, Yoshinori
Iwata, Hiroji
Masuda, Norikazu
Mukai, Hirofumi
Saji, Shigehira
Ikeda, Takafumi
Haga, Hironori
Saeki, Toshiaki
Aogi, Kenjiro
Sugie, Tomoharu
Ueno, Takayuki
Ohno, Shinji
Ishiguro, Hiroshi
Kanbayashi, Chizuko
Miyamoto, Takeshi
Hagiwara, Yasuhiro
Toi, Masakazu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-023-07099-4
- URN
-
urn:nbn:de:101:1-2023123021090791466931
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Takada, Masahiro
- Imoto, Shigeru
- Ishida, Takanori
- Ito, Yoshinori
- Iwata, Hiroji
- Masuda, Norikazu
- Mukai, Hirofumi
- Saji, Shigehira
- Ikeda, Takafumi
- Haga, Hironori
- Saeki, Toshiaki
- Aogi, Kenjiro
- Sugie, Tomoharu
- Ueno, Takayuki
- Ohno, Shinji
- Ishiguro, Hiroshi
- Kanbayashi, Chizuko
- Miyamoto, Takeshi
- Hagiwara, Yasuhiro
- Toi, Masakazu
- SpringerLink (Online service)
Other Objects (12)
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer
Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
The impact of CBP expression in estrogen receptor-positive breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Role of BRD4 and histone acetylation in estrogen receptor-positive breast cancers
Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer
Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
The impact of CBP expression in estrogen receptor-positive breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Role of BRD4 and histone acetylation in estrogen receptor-positive breast cancers
Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer
Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
The impact of CBP expression in estrogen receptor-positive breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Role of BRD4 and histone acetylation in estrogen receptor-positive breast cancers